Ordering
Ordering susceptibility tests
ZERBAXA®
(ceftolozane and tazobactam) for injection (1.5 g), for intravenous use
Ordering
Ordering susceptibility tests
To order clinical isolates to perform verification testing for ceftolozane and tazobactam, contact the CDC or send requests via the following link: www.cdc.gov/drugresistance/resistance-bank/currently-available.html.
Ceftolozane and tazobactam susceptibility disks are available from Hardy Diagnostics.
Visit hardydiagnostics.com for complete instructions for use or call 1-800-266-2222.
Description | Catalog number |
---|---|
Ceftolozane/tazobactam 1x50 cartridge (30 mg/10 μg) | Z9341 |
Ceftolozane/tazobactam 5x50 cartridge (30 mg/10 μg) | Z9345 |
Pathogen | Minimum inhibitory concentrations (mcg/mL) | Disk diffusion zone diameter (mm) | ||||
---|---|---|---|---|---|---|
Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | |
Enterobacteriaceae | ≤2/4 | 4/4 | ≥8/4 | ≥21 | 18–20 | ≤17 |
Pseudomonas aeruginosa | ≤4/4 | 8/4 | ≥16/4 | ≥21 | 17–20 | ≤16 |
HardyDisk is a registered trademark of Hardy Diagnostics.
Ceftolozane and tazobactam are available from Thermo Fisher Scientific on Microbroth Dilution Thermo ScientificTM SensititreTM Custom MIC Plates.
For more information, contact your local representative at microbiology@thermofisher.com or visit thermofisher.com/AST.
Pathogen | Minimum inhibitory concentrations (mcg/mL) | ||
---|---|---|---|
Susceptible | Intermediate | Resistant | |
Enterobacteriaceae | ≤2/4 | 4/4 | ≥8/4 |
Pseudomonas aeruginosa | ≤4/4 | 8/4 | ≥16/4 |
(a) The Sensititre 18–24 hour MIC or breakpoint susceptibility system with ceftolozane and tazobactam is FDA-cleared in the dilution range of 0.03/4-64/4 μg/mL.
Thermo Scientific and Sensititre are trademarks of Thermo Fisher Scientific Inc. and its subsidiaries.
Ceftolozane and tazobactam ETEST ® C/T 256 strips are available from bioMérieux.
For ordering information, visit biomerieux-usa.com/clinical/etest.
Description | μg/mL | Strips/box | Ref. |
---|---|---|---|
ETEST® ceftolozane/tazobactam |
Each strip contains:
|
Single pack: 30 strips | 414 445 |
Pathogen | Minimum inhibitory concentrations (mcg/mL) | ||
---|---|---|---|
Susceptible | Intermediate | Resistant | |
Enterobacteriaceae | ≤2/4 | 4/4 | ≥8/4 |
Pseudomonas aeruginosa | ≤4/4 | 8/4 | ≥16/4 |
ETEST is a registered trademark of bioMérieux SA or one of its subsidiaries.
AST = antimicrobial susceptibility testing
CLSI = Clinical and Laboratory Standards Institute
MIC = minimum inhibitory concentration
ZERBAXA is indicated in adult patients for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.
ZERBAXA used in combination with metronidazole is indicated in adult patients for the treatment of complicated intra-abdominal infections (cIAI) caused by the following Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Before prescribing ZERBAXA, please read the accompanying Prescribing Information.